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HIV-1 Integrase (IN) is an attractive and validated target for developing novel antiretroviral 
agents. [1-3]. Because of its vital role in the viral replication cycle, with no human 
counterpart of the enzyme known, the addition of an IN inhibitor to existing components of 
antiretroviral therapy is expected to improve the outcome of therapy by potential 
synergism, without exacerbating toxicity issues.   
In the past several years, a plethora of compounds with diverse structural features have 
been reported as IN inhibitors [4]. Several of them inhibit both the viral enzyme and viral 
replication in cell-based assays as well as in animal models. However, as of today, no 
inhibitor of HIV-1 IN has been approved. Recently, a class of compounds bearing a β-
diketo acid moiety, independently discovered by scientists from Shionogi & Co. Ltd. and 
Merck Research Laboratories, have emerged as the most promising lead in anti-HIV-1 IN 
drug discovery [5]. It is believed that the β-diketo acid pharmacophoric motif could be 
involved in a functional sequestration of one or both divalent metal ions, which are critical 
cofactors at the enzyme catalytic site [6]. This would subsequently block the transition state 
of the IN-DNA complex. In this scenario, it is of paramount importance to acquire 
information about the mode of action of diketo acids, which could then be useful in the 
design of new compounds as IN inhibitors. 
Starting from the hypothesis that these inhibitors are able to coordinate ions in solution 
before interacting on the active site, a series of potentiometric measurements have been 
performed to understand the coordination ability of the diketo acid pharmacophore towards 
the biologically relevant ion Mg2+. Moreover, by using β-diketo acid/ester (1-4) as model 
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ligands with a set of divalent metal ions (Mg, Mn, Ni, Co, Cu, Zn), we obtained a series of 
complexes and tested them for anti-HIV-1 IN activity. Results demonstrate that the diketo 
acid functionality chelates divalent metal ions in solution and complexes with metals in 
different stoichiometric ratios are isolated. We postulate that the diketoacids act as 
complexes in their active form.  In particular, they predominantly form species such as 
Mg2L2+ and Mg2L2 (derived from diketo acids 1 and 3, H2L), and MgL+ and MgL2 (derived 
from diketo esters 2 and 4, HL) at physiological pH. Furthermore, the synthesized mono- 
and dimetallic complexes inhibited IN at a high nanomolar to low micromolar range, with 
metal-dependency in the phenyl-diketoacid series.  Retrospective analysis suggests that the 
electronic properties of the aromatic framework influence the metal-chelating ability of the 
diketo acid system. Therefore, the difference in activities is related to the complexes they 
preferentially form in solution, and these findings are important for the design of a new 
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